Nifeviroc

• CAT Number: I008293
• CAS Number: 934740-33-7
• Molecular Formula: C33H42N4O6
• Molecular Weight: 590.72
• Purity: ≥95%
• Target: CCR5 antagonist
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C33H42N4O6/c1-2-18-36(32(39)43-23-25-12-14-30(15-13-25)37(41)42)29-16-19-34(20-17-29)21-28-22-35(31(38)26-8-6-7-9-26)24-33(28,40)27-10-4-3-5-11-27/h2-5,10-15,26,28-29,40H,1,6-9,16-24H2/t28-,33-/m0/s1
• InChIKey: JNSKQYZFEVKYDB-UVMMSNCQSA-N
• SMILES: O=C(OCC1=CC=C([N+]([O-])=O)C=C1)N(C2CCN(C[C@H]3CN(C(C4CCCC4)=O)C[C@]3(O)C5=CC=CC=C5)CC2)CC=C

Nifeviroc (Cat.No:I008293) is a novel antiretroviral drug under investigation for the treatment of HIV-1 infection. It belongs to the class of CCR5 antagonists and works by blocking the CCR5 receptor, preventing HIV from entering human immune cells. Early studies show promising results in reducing viral load and improving immune function, offering hope for more effective HIV therapies in the future.

Reference

1:J Pharm Biomed Anal. 2011 Nov 1;56(3):637-40. doi: 10.1016/j.jpba.2011.06.027. Epub 2011 Jul 5. Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study.Wu W,Xie D,Cheng Z,Liu Z,Ran L,Gu Z,Yu P, PMID: 21802236 DOI: 10.1016/j.jpba.2011.06.027 Abstract: Nifeviroc is a novel CCR5 antagonist used for the treatment of HIV type-1 infection. A LC-ESI-MS/MS method for the determination of nifeviroc in human plasma was developed and validated. The calibration curve (r(2)=0.9993) of nifeviroc was established at the range of 1.924-2935 μg L(-1). The intra- and inter-day precisions (RSD%) were all less than 7%, and the accuracies at three concentration levels were all within 100 ± 5%. This validated method was then successfully applied to a pharmacokinetic study in health Chinese volunteers.Copyright © 2011 Elsevier B.V. All rights reserved.